Market Overview:
The global erwinia asparaginase market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of leukemia and other blood cancers, rising demand for effective and safe cancer therapies, and growing focus on personalized medicine. The global erwinia asparaginase market is segmented by type into Escherichia coli, Erwinia Chrysanthemi, and Pegylated. The Escherichia coli segment is expected to account for the largest share of the global erwinia asparaginase market in 2018. This segment is also projected to grow at the highest CAGR during the forecast period. The growth in this segment can be attributed to its high efficacy and safety profile compared with other types of erwinia asparaginases. The global erwinia asparaginase market is also divided by application into acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and other applications.
Product Definition:
Erwinia Asparaginase is an enzyme that breaks down the amino acid asparagine into simpler components. This enzyme is important for cancer patients because it helps to stop the growth of cancer cells.
Escherichia coli:
Escherichia coli is a gram-positive bacteria that occurs in the human gut as well as other places in the environment. It is commonly known as E. coli and is one of the most common causes of diarrhea. The species has over 2,000 different strains, some of which are useful for making proteins and others that can be used to produce vitamin D3 (calcifediol).
Erwinia Chrysanthemi:
Erwinia chrysanthhemi is a gram-positive bacteria belonging to the family Enterobacteriaceae. The species was first discovered in 1879 and was named after American botanist Erwinia chrysanthemi, who found it in Japan. E.
Application Insights:
Acute lymphoblastic leukemia (ALL) was the leading application segment in 2017 and accounted for a market share of over 80%. The product is used as an alternative to autophagy-related protein 4 (ATP4) enzyme replacement therapy. It is also under investigation as a potential therapeutic option for other blood cancers such as myelodysplastic syndrome and acute myelogenous leukemia.
The other applications include use in genetic diseases, cancer, diabetes mellitus type 2, Parkinson¢â‚¬â„¢s disease and various others. Erwinia asparaginase finds limited usage owing to its non-clinical toxicology profile; however, it has been studied extensively in preclinical models of these aforementioned diseases that are associated with high unmet medical needs across the globe.
Inherited disorders caused by mutations or deletions in genes encoding proteins responsible for cell growth & death are known as genetic diseases.
Regional Analysis:
North America dominated the global market in 2017. This is attributed to the presence of a large number of key players, high adoption of EAWase treatment, and favorable reimbursement policies for Erwinia asparaginase therapy. In addition, increasing R&D activities by major companies to develop novel therapies will drive growth over the forecast period. Asia Pacific is expected to witness lucrative growth during the forecast period owing to untapped opportunities in this region along with rising awareness about advanced cancer treatments and their benefits. Moreover, availability of low-cost raw materials such as bovine serum will also help boost revenue generation in APAC during the same period (2018-2030).
Moreover, growing healthcare expenditure levels coupled with improving economic conditions are anticipated to fuel regional demand for medical products over next eight years (2018-2030).
Growth Factors:
- Increasing incidence of cancer: The increasing incidence of cancer is the major growth driver for the Erwinia asparaginase market. According to a study by World Health Organization (WHO), it is estimated that around 14 million new cases of cancer were diagnosed in 2012 and this number is expected to rise to 24 million by 2035. This will create a high demand for Erwinia asparaginase, which is used in the treatment of various types of cancers.
- Rising awareness about Erwinia asparaginase therapy: There has been an increase in the awareness about Erwinia asparaginase therapy among patients and healthcare professionals over the past few years. This has led to an increase in its adoption, thereby driving the growth of the market.
- Technological advancements: The development of novel technologies for manufacturing Erwinia asparaginase products has helped reduce their cost and improved their efficacy, thus boosting their demand worldwide.
Scope Of The Report
Report Attributes
Report Details
Report Title
Erwinia Asparaginase Market Research Report
By Type
Escherichia coli, Erwinia Chrysanthemi, Pegylated
By Application
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Other
By Companies
Jazz Pharmaceuticals, Shire, Medac GmbH, Kyowa Hakko Kirin, Qianhong Bio-pharma, Taj Pharmaceuticals, Mingxing Pharma, SL Pharma, United Biotech
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
124
Number of Tables & Figures
87
Customization Available
Yes, the report can be customized as per your need.
Global Erwinia Asparaginase Market Report Segments:
The global Erwinia Asparaginase market is segmented on the basis of:
Types
Escherichia coli, Erwinia Chrysanthemi, Pegylated
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Jazz Pharmaceuticals
- Shire
- Medac GmbH
- Kyowa Hakko Kirin
- Qianhong Bio-pharma
- Taj Pharmaceuticals
- Mingxing Pharma
- SL Pharma
- United Biotech
Highlights of The Erwinia Asparaginase Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Escherichia coli
- Erwinia Chrysanthemi
- Pegylated
- By Application:
- Acute Lymphoblastic Leukemia
- Acute Myeloid Leukemia
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Erwinia Asparaginase Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Erwinia asparaginase is an enzyme that catalyzes the conversion of asparagine to glutamine. This process is important for the growth of bacteria and fungi, and can be used in the production of antibiotics.
Some of the major players in the erwinia asparaginase market are Jazz Pharmaceuticals, Shire, Medac GmbH, Kyowa Hakko Kirin, Qianhong Bio-pharma, Taj Pharmaceuticals, Mingxing Pharma, SL Pharma, United Biotech.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Erwinia Asparaginase Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Erwinia Asparaginase Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Erwinia Asparaginase Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Erwinia Asparaginase Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Erwinia Asparaginase Market Size & Forecast, 2020-2028
4.5.1 Erwinia Asparaginase Market Size and Y-o-Y Growth
4.5.2 Erwinia Asparaginase Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Escherichia coli
5.2.2 Erwinia Chrysanthemi
5.2.3 Pegylated
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Acute Lymphoblastic Leukemia
6.2.2 Acute Myeloid Leukemia
6.2.3 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Erwinia Asparaginase Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Erwinia Asparaginase Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Escherichia coli
9.6.2 Erwinia Chrysanthemi
9.6.3 Pegylated
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Acute Lymphoblastic Leukemia
9.10.2 Acute Myeloid Leukemia
9.10.3 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Escherichia coli
10.6.2 Erwinia Chrysanthemi
10.6.3 Pegylated
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Acute Lymphoblastic Leukemia
10.10.2 Acute Myeloid Leukemia
10.10.3 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Escherichia coli
11.6.2 Erwinia Chrysanthemi
11.6.3 Pegylated
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Acute Lymphoblastic Leukemia
11.10.2 Acute Myeloid Leukemia
11.10.3 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Escherichia coli
12.6.2 Erwinia Chrysanthemi
12.6.3 Pegylated
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Acute Lymphoblastic Leukemia
12.10.2 Acute Myeloid Leukemia
12.10.3 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Escherichia coli
13.6.2 Erwinia Chrysanthemi
13.6.3 Pegylated
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Acute Lymphoblastic Leukemia
13.10.2 Acute Myeloid Leukemia
13.10.3 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Erwinia Asparaginase Market: Competitive Dashboard
14.2 Global Erwinia Asparaginase Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Jazz Pharmaceuticals
14.3.2 Shire
14.3.3 Medac GmbH
14.3.4 Kyowa Hakko Kirin
14.3.5 Qianhong Bio-pharma
14.3.6 Taj Pharmaceuticals
14.3.7 Mingxing Pharma
14.3.8 SL Pharma
14.3.9 United Biotech
